Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:02:28.940Z.
Calculation as of: 2026-10-06T15:02:28.940Z.
Quote observation: 2026-10-06T15:00:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$213.31M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $198.76M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $209.84M | N/A | 25.58 | 25.58 | 25.58 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $213.31M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $214.16M | 6.03 | 6.53 | 42.60 | 42.60 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $190.17M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.79M | 14.47 | 22.48 | 68.28 | 68.28 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.19M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $224.44M | N/A | 26.24 | 26.24 | 26.24 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.53M | 1.09 | 2.35 | 8.36 | 8.36 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
